Organon First Quarter 2023 Earnings - " ORGANON" Disclaimer statement Cautionary Note Regarding Forward-Looking Statements Except for historical information, this press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects. Forward-looking statements may be identified by word ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified in its charter) Del ...

Organon & Co (NYSE:OGN) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley Umer Raffat - Evercore ISI Navann Ty - BNP Paribas Exane Gregory Fraser - Truist Securities Stephen Scala - Cowen and Company Christopher Schott - JPMorgan Chase & Co. David Amsellem - Piper Sandler & Co. Operator Ladies and gentlemen, thank you for standing by. At ...

Organon & Co. (NYSE:OGN) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this morning with the Organon management team. From the company, we have CEO, Kevin Ali, as well as CFO, Matt Walsh. So Kevin and Matt, Happy New Year, and thanks for joining us this m ...

Organon & Co. (NYSE:OGN) Piper Sandler 34th Annual Healthcare Conference November 29, 2022 9:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler David Amsellem Okay. Good morning. Welcome to the 34th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the specialty pharma team, Eric [ph] Piper. Our next company Fireside Chat is Organon and we're delighted to have Kevin Ali, CEO and ...

Organon Q3 2022 Earnings · · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q3 2022 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance a ...

Organon & Co. (NYSE:OGN) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Sandra Milligan – Head of R&D Conference Call Participants Terence Flynn – Morgan Stanley Umer Raffat – Evercore ISI David Amsellem – Piper Sandler Jason Gerberry – BofA Greg Fraser – Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I wo ...

Organon & Co. (NYSE:OGN) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Sandra Milligan - Head, R&D Conference Call Participants Jason Gerberry - Bank of America Umer Raffat - Evercore David Amsellem - Piper Sandler Greg Fraser - Truist Securities Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone ...

Organon Q2 2022 Earnings · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q2 2022 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and ...

Organon Q1 2022 Earnings · · ORGANON™ Disclaimer statement This text should be viewed in conjunction with Organon's Q1 2022 earnings call Safe Harbor for Forward-Looking Statements Except for historical information herein, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and ...